#United States #Avirmax Biopharma #Denver #gene therapy #ARVO

Avirmax Biopharma Inc. at the 2026 ARVO Annual Meeting

Avirmax Biopharma Inc., based in Hayward, California, is poised to make significant contributions to the field of ocular genetics at the upcoming 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), scheduled from May 3-7, 2026, in Denver, Colorado. This premier event, recognized as the largest international gathering focused on ophthalmology and related visual sciences, offers a platform for cutting-edge research and networking.

The company will showcase two pivotal scientific presentations designed to advance the understanding of gene therapies for ocular disorders. The first presentation, titled "Analytical Integration of ddPCR and Protein Quantification Enhances Accuracy of AAV-Specific Vector Genome Determination," will be delivered by Dr. Sameera Peraramelli on May 5, 2026, during the session devoted to Gene Editing and Gene Therapy II.

Dr. Shengjiang Liu, the Chief Executive and Scientific Officer of Avirmax, will present another critical research finding titled "From Bench to Clinic: CMC and Preclinical Development of ABI-110 Gene Therapy for Ocular Neovascularized Disorders". His presentation will occur as a poster session on the same day from 3:30 PM to 5:15 PM MDT. Both presentations are set against the backdrop of Avirmax's ongoing commitment to enhancing ocular genetic medicine, particularly through innovations in its proprietary macular targeting capsid AAV.N54.

Avirmax's research emphasizes the necessity for precise vector genome titer determination, pivotal for accurate dosing in clinical applications. This is particularly urgent for treatments addressing conditions like wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV). With a focus on rigorous nonclinical models, the company is poised to set new standards in the delivery of gene therapies.

In addition to the presentations, Avirmax Biopharma will feature its latest innovations at Booth #5028. Attendees are invited to visit and engage with the team, who will be exhibiting comprehensive data packages and other advancements in the field of ocular gene therapy.

Founded with the mission to provide safe and effective rAAV-mediated therapeutics for ocular diseases, Avirmax Biopharma leverages advanced AAV engineering technologies alongside an Sf9-based manufacturing platform. Their goal is clear: to fulfill unmet patient needs with accessible gene therapies that promise to transform treatment paradigms in ophthalmology.

For anyone interested in learning more about Avirmax Biopharma's innovative approaches and the ongoing developments in ocular genetics, we encourage you to explore their official website at avirmax.com.

As the ARVO 2026 Annual Meeting approaches, the excitement surrounding Avirmax's contributions signifies a noteworthy step in the evolution of ocular healthcare, bringing renewed hope to patients affected by debilitating visual disorders.